BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31978505)

  • 1. Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue.
    Deftereos G; Sandoval A; Furtado LV; Bronner M; Matynia AP
    Hum Pathol; 2020 Mar; 97():52-59. PubMed ID: 31978505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry Profile Predicts
    Li W; Niehaus AG; O'Neill SS
    Int J Surg Pathol; 2020 Aug; 28(5):502-506. PubMed ID: 32114861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
    Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample features associated with success rates in population-based EGFR mutation testing.
    Shiau CJ; Babwah JP; da Cunha Santos G; Sykes JR; Boerner SL; Geddie WR; Leighl NB; Wei C; Kamel-Reid S; Hwang DM; Tsao MS
    J Thorac Oncol; 2014 Jul; 9(7):947-956. PubMed ID: 24922009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting.
    Udupa KS; Rajendranath R; Sagar TG; Sundersingh S; Joseph T
    Indian J Cancer; 2015; 52(3):266-8. PubMed ID: 26905105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.
    Thunnissen E; Boers E; Heideman DA; Grünberg K; Kuik DJ; Noorduin A; van Oosterhout M; Pronk D; Seldenrijk C; Sietsma H; Smit EF; van Suylen R; von der Thusen J; Vrugt B; Wiersma A; Witte BI; den Bakker M
    Virchows Arch; 2012 Dec; 461(6):629-38. PubMed ID: 23064619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
    Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
    Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
    Xiong Y; Bai Y; Leong N; Laughlin TS; Rothberg PG; Xu H; Nong L; Zhao J; Dong Y; Li T
    Diagn Pathol; 2013 Feb; 8():27. PubMed ID: 23419122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
    Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
    Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
    Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
    Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas.
    Shanzhi W; Yiping H; Ling H; Jianming Z; Qiang L
    PLoS One; 2014; 9(4):e95479. PubMed ID: 24743427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
    BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.
    Wen YH; Brogi E; Hasanovic A; Ladanyi M; Soslow RA; Chitale D; Shia J; Moreira AL
    Mod Pathol; 2013 Sep; 26(9):1197-203. PubMed ID: 23599147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.
    Jie-Liu ; Li XY; Zhao YQ; Liu RQ; Zhang JB; Ma J; Chen LJ; Hu XF
    Pathol Res Pract; 2014 Mar; 210(3):176-81. PubMed ID: 24370340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.
    Kanmaz ZD; Aras G; Tuncay E; Bahadır A; Kocatürk C; Yaşar ZA; Öz B; Özkurt CÜ; Gündoğan C; Çermik TF
    Cancer Biomark; 2016; 16(3):489-98. PubMed ID: 27062706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutation testing in pulmonary adenocarcinoma: evaluation of tumor cell number and tumor percent in paraffin sections of 120 small biopsies.
    Scarpino S; Pulcini F; Di Napoli A; Giubettini M; Ruco L
    Lung Cancer; 2015 Jan; 87(1):8-13. PubMed ID: 25468201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.